Search This Blog

Saturday, June 27, 2009

Oral Insulin Reduced Glucose Levels in Pre-Clinical Trials

Oral Insulin Cobalamini has been shown to considerably reduce sugar levels when tested on animals. This is as per announcement of Access Pharmaceuticals. They used some formulas of Cobalamini that are based on the body's natural absorption of Vitamin B12. They plan to do more pre-clinical tests.

Hopefully, this will be a success especially for people who have to do multiple insulin injection daily. This emerging company already has patents on Vitamin B12 to carry drugs. It will transfer this to the blood for easier absorption. Cobalamini therefore has the potential to deliver insulin orally or improve the delivery system currently in use.

Senior Vice President of Access Pharmaceuticals' Research and Development, Dr. David P. Nowotnik said that the company has data to use this method with different proteins but the result of the pre-clinical trials delighted them as there is indication that desired effect can be attained.

Access Pharmaceuticals plans to collaborate with other companies in the development of this oral delivery device. They have conducted studies with top pharmaceutical companies but are looking for partners to do more research on the availability of oral insulin.

CEO and Access Pharmaceutical Stephen R. Seiler said they're excited by the results of the research they conducted on animals. The potential for an oral delivery system for insulin is indicated. The Cobalamini technology, he said, can be applied to some cancer products as well.

People with diabetes I am sure will just be too happy not to have anymore of insulin resistance if they could take it by mouth as this will eliminate the irritation to the skin due to multiple injection. In another study, The American Chemical Society has known of this issue since their 222nd national meeting.

They were told at the meeting that the material is a polymer, the consistency of which is gel-like. This will offer another way or in place of injecting the insulin every day. A graduate student named Aaron C. Foss of Purdue University conducted a study on this issue with the guidance of the professor of biomedical and chemical engineering, Nicholas A. Peppas, ScD.

You see, the polymer is supposed to protect the insulin until it enters the small intestine. There, the blood will absorb it without it being exposed to the acidic hazards in the mouth first, then onto the throat and stomach. Researchers before this had only a minimum amount of insulin left for the blood to absorb but Peppas is confident this will not happen with their own research.

Why? Because the small intestine is less acidic than the other places where the insulin has to pass through So once the insulin gets to the small intestine, the polymer swells up. In addition, the polymer intercepts the calcium which is a good thing because the walls of the small intestine need to have the pores tightly sealed. Then as soon as they open up, the insulin can slip through to the blood. Sneaky, huh?

They have been working on this for some time so I looked for any report on the progress but I failed. So if any good soul out there who will be successful in this detective work, please let me know as I am truly interested to know the result of this investigation on oral insulin.